JP2009545609A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009545609A5 JP2009545609A5 JP2009522936A JP2009522936A JP2009545609A5 JP 2009545609 A5 JP2009545609 A5 JP 2009545609A5 JP 2009522936 A JP2009522936 A JP 2009522936A JP 2009522936 A JP2009522936 A JP 2009522936A JP 2009545609 A5 JP2009545609 A5 JP 2009545609A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- agonist
- chemotherapeutic agent
- tumor
- manufacture
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000002246 antineoplastic agent Substances 0.000 claims description 33
- 239000000556 agonist Substances 0.000 claims description 31
- 229940127089 cytotoxic agent Drugs 0.000 claims description 31
- 239000000203 mixture Substances 0.000 claims description 27
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims description 26
- 206010028980 Neoplasm Diseases 0.000 claims description 18
- 238000004519 manufacturing process Methods 0.000 claims description 17
- 238000000034 method Methods 0.000 claims description 16
- 108010091477 IRL 1620 Proteins 0.000 claims description 10
- 229930012538 Paclitaxel Natural products 0.000 claims description 10
- DXPHNGAMYPPTBJ-TZMIJSMNSA-N irl 1620 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CCC(O)=O)C(C)C)C1=CN=CN1 DXPHNGAMYPPTBJ-TZMIJSMNSA-N 0.000 claims description 10
- 229960001592 paclitaxel Drugs 0.000 claims description 10
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims description 10
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims description 8
- 229960004679 doxorubicin Drugs 0.000 claims description 8
- 229960002949 fluorouracil Drugs 0.000 claims description 8
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 claims description 5
- KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 claims description 5
- 102000006992 Interferon-alpha Human genes 0.000 claims description 5
- 108010047761 Interferon-alpha Proteins 0.000 claims description 5
- 102000003996 Interferon-beta Human genes 0.000 claims description 5
- 108090000467 Interferon-beta Proteins 0.000 claims description 5
- 102000008070 Interferon-gamma Human genes 0.000 claims description 5
- 108010074328 Interferon-gamma Proteins 0.000 claims description 5
- 102000000588 Interleukin-2 Human genes 0.000 claims description 5
- 108010002350 Interleukin-2 Proteins 0.000 claims description 5
- 101710205037 Sarafotoxin Proteins 0.000 claims description 5
- 229940009456 adriamycin Drugs 0.000 claims description 5
- 230000036770 blood supply Effects 0.000 claims description 5
- 229940127093 camptothecin Drugs 0.000 claims description 5
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 claims description 5
- 229960004562 carboplatin Drugs 0.000 claims description 5
- 190000008236 carboplatin Chemical compound 0.000 claims description 5
- 229960004316 cisplatin Drugs 0.000 claims description 5
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims description 5
- 229960000975 daunorubicin Drugs 0.000 claims description 5
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 claims description 5
- VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 claims description 5
- 229940044627 gamma-interferon Drugs 0.000 claims description 5
- 229960004768 irinotecan Drugs 0.000 claims description 5
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 claims description 5
- 229960000303 topotecan Drugs 0.000 claims description 5
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 claims description 5
- 108050009340 Endothelin Proteins 0.000 claims description 4
- 102000002045 Endothelin Human genes 0.000 claims description 4
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims description 4
- 201000011510 cancer Diseases 0.000 claims description 4
- 229960003668 docetaxel Drugs 0.000 claims description 4
- ZUBDGKVDJUIMQQ-UBFCDGJISA-N endothelin-1 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@H]2CSSC[C@@H](C(N[C@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)NC(=O)[C@@H](CO)NC(=O)[C@H](N)CSSC1)C1=CNC=N1 ZUBDGKVDJUIMQQ-UBFCDGJISA-N 0.000 claims description 4
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- 206010019695 Hepatic neoplasm Diseases 0.000 claims description 2
- 208000007766 Kaposi sarcoma Diseases 0.000 claims description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 2
- 208000029610 breast phyllodes tumor Diseases 0.000 claims description 2
- 208000029742 colonic neoplasm Diseases 0.000 claims description 2
- 208000014018 liver neoplasm Diseases 0.000 claims description 2
- 201000001441 melanoma Diseases 0.000 claims description 2
- 206010027191 meningioma Diseases 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 208000023958 prostate neoplasm Diseases 0.000 claims description 2
- 229940044683 chemotherapy drug Drugs 0.000 description 2
- KIYSPBOGUDIMPC-SCGUGKIPSA-N 4-ala-endothelin-1 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)OC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H](N)[C@@H](C)CC)NC(=O)[C@H](C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(=O)OC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](C)N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](N)CCSC)C(C)C)C1C=NC=N1 KIYSPBOGUDIMPC-SCGUGKIPSA-N 0.000 description 1
- -1 docetacel Chemical compound 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11/461,961 US20070032422A1 (en) | 2002-10-24 | 2006-08-02 | Methods, compositions and articles of manufacture for contributing to the treatment of cancers |
| PCT/US2007/074036 WO2008016793A2 (en) | 2006-08-02 | 2007-07-20 | Methods, compositions and articles of manufacture for contributing to the treatment of cancers |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009545609A JP2009545609A (ja) | 2009-12-24 |
| JP2009545609A5 true JP2009545609A5 (https=) | 2011-07-28 |
Family
ID=38752363
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009522936A Pending JP2009545609A (ja) | 2006-08-02 | 2007-07-20 | 癌の治療に寄与する方法、組成物および製造物品 |
Country Status (17)
| Country | Link |
|---|---|
| US (4) | US20070032422A1 (https=) |
| EP (2) | EP2046323B1 (https=) |
| JP (1) | JP2009545609A (https=) |
| KR (1) | KR101507178B1 (https=) |
| CN (1) | CN101522186B (https=) |
| AR (1) | AR062177A1 (https=) |
| BR (1) | BRPI0715521A2 (https=) |
| CA (1) | CA2658340C (https=) |
| DK (1) | DK2046323T3 (https=) |
| ES (1) | ES2402232T3 (https=) |
| IL (1) | IL196825A (https=) |
| MX (1) | MX2009001233A (https=) |
| NO (1) | NO20090915L (https=) |
| RU (1) | RU2407527C2 (https=) |
| TW (1) | TWI469776B (https=) |
| WO (1) | WO2008016793A2 (https=) |
| ZA (1) | ZA200900017B (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8026216B2 (en) | 2002-10-24 | 2011-09-27 | Spectrum Pharmaceuticals, Inc. | Methods and compositions for contributing to the treatment of cancers |
| US20070032422A1 (en) | 2002-10-24 | 2007-02-08 | Spectrum Pharmaceuticals, Inc. | Methods, compositions and articles of manufacture for contributing to the treatment of cancers |
| EP2059254B1 (en) | 2006-08-31 | 2015-04-08 | Spectrum Pharmaceuticals, Inc. | Sensitization of tumor cells to radiation therapy through the administration of endothelin agonists |
| CN101888851B (zh) * | 2007-08-21 | 2013-11-20 | 美国中西部大学 | 使用内皮缩血管肽b受体激动剂治疗中风或脑血管意外的组合物 |
| US9308235B2 (en) | 2012-05-09 | 2016-04-12 | Spectrum Pharmaceuticals, Inc. | Treatment of primary and metastatic carcinoma |
| ES2971441T3 (es) * | 2016-05-06 | 2024-06-05 | Biodynamic Res Foundation | Composición farmacéutica que contiene un fármaco macromolecular |
| KR20260005957A (ko) * | 2023-04-26 | 2026-01-12 | 바이오셀즈(베이징) 바이오테크 코., 엘티디. | 폴리펩티드 및 이의 응용 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5550110A (en) | 1992-04-22 | 1996-08-27 | Warner-Lambert Company | Endothelin Antagonists II |
| CA2135151A1 (en) | 1993-11-08 | 1995-05-09 | Mitsuhiro Wakimasu | Cyclic hexapeptides, their production and use |
| US5811416A (en) | 1994-06-06 | 1998-09-22 | Board Of Regents The University Of Texas System | Endothelin antagonist and/or endothelin synthase inhibitor in combination with a progestin, an estrogen, a cyclooxygenase inhibitor, or a nitric acid donor or substrate |
| US5612359A (en) | 1994-08-26 | 1997-03-18 | Bristol-Myers Squibb Company | Substituted biphenyl isoxazole sulfonamides |
| EP2301562B1 (en) | 1994-12-12 | 2013-04-17 | Omeros Corporation | Irrigation solution and method for inhibition of pain, inflammation and spasm |
| US6251861B1 (en) | 1996-06-27 | 2001-06-26 | Takeda Chemical Industries, Ltd. | Treatment of cerebral infarction using cyclic hexapeptides |
| EP0950418A2 (en) | 1998-04-14 | 1999-10-20 | Takeda Chemical Industries, Ltd. | Composition for preventing or treating ischemic disease |
| CA2342981A1 (en) | 1998-09-25 | 2000-04-06 | Warner-Lambert Company | Chemotherapy of cancer with acetyldinaline in combination with gemcitabine, capecitabine or cisplatin |
| US7566452B1 (en) | 1999-05-04 | 2009-07-28 | New York University | Cancer treatment with endothelin receptor antagonists |
| US6545048B1 (en) | 1999-06-29 | 2003-04-08 | California Institute Of Technology | Compositions and methods of treating cancer using compositions comprising an inhibitor or endothelin receptor activity |
| US6635677B2 (en) | 1999-08-13 | 2003-10-21 | Case Western Reserve University | Methoxyamine combinations in the treatment of cancer |
| WO2001091736A2 (en) | 2000-05-31 | 2001-12-06 | Warner-Lambert Company | Combinations of an endothelin receptor antagonist and an antiepileptic compound having pain alleviating properties or analgesic |
| WO2002049630A2 (en) | 2000-12-21 | 2002-06-27 | Bristol-Myers Squibb Company | Method for preventing or treating pain by administering an endothelin antagonist |
| WO2003009805A2 (en) | 2001-07-23 | 2003-02-06 | Brigham And Women's Hospital, Inc. | Analgesic methods using endothelin receptor ligands |
| US7973064B2 (en) | 2001-11-27 | 2011-07-05 | The Board Of Trustees Of The University Of Illinois | Method and composition for potentiating an opiate analgesic |
| US20030229004A1 (en) | 2002-03-20 | 2003-12-11 | Pangene Corporation | Modulation of tumor cells using BER inhibitors in combination with a sensitizing agent and DSBR inhibitors |
| US20070032422A1 (en) | 2002-10-24 | 2007-02-08 | Spectrum Pharmaceuticals, Inc. | Methods, compositions and articles of manufacture for contributing to the treatment of cancers |
| JP2006508086A (ja) | 2002-10-24 | 2006-03-09 | ザ ボード オブ トラスティーズ オブ ザ ユニバーシティ オブ イリノイ | 固形腫瘍を予防および治療するための方法および組成物 |
| US8217010B2 (en) * | 2002-10-24 | 2012-07-10 | The Board Of Trustees Of The University Of Illinois | Methods, compositions and articles of manufacture for contributing to the treatment of solid tumors |
| US8026216B2 (en) | 2002-10-24 | 2011-09-27 | Spectrum Pharmaceuticals, Inc. | Methods and compositions for contributing to the treatment of cancers |
| EP1819367B1 (en) | 2004-11-22 | 2013-11-20 | The Board Of Trustees Of The University Of Illinois | Use of the endothelin etb receptor agonists irl-1620 in tumor imaging |
| JP2008531589A (ja) * | 2005-02-22 | 2008-08-14 | スペクトラム・ファーマシューティカルス・インコーポレーテッド | 固形腫瘍の治療に貢献するための方法、組成物及び製品 |
| EP2059254B1 (en) | 2006-08-31 | 2015-04-08 | Spectrum Pharmaceuticals, Inc. | Sensitization of tumor cells to radiation therapy through the administration of endothelin agonists |
-
2006
- 2006-08-02 US US11/461,961 patent/US20070032422A1/en not_active Abandoned
-
2007
- 2007-07-20 EP EP07799742A patent/EP2046323B1/en not_active Not-in-force
- 2007-07-20 RU RU2009107085/14A patent/RU2407527C2/ru not_active IP Right Cessation
- 2007-07-20 KR KR1020097001590A patent/KR101507178B1/ko not_active Expired - Fee Related
- 2007-07-20 CN CN2007800288089A patent/CN101522186B/zh not_active Expired - Fee Related
- 2007-07-20 MX MX2009001233A patent/MX2009001233A/es active IP Right Grant
- 2007-07-20 DK DK07799742.7T patent/DK2046323T3/da active
- 2007-07-20 EP EP12153542A patent/EP2450037A1/en not_active Withdrawn
- 2007-07-20 BR BRPI0715521-2A patent/BRPI0715521A2/pt not_active IP Right Cessation
- 2007-07-20 JP JP2009522936A patent/JP2009545609A/ja active Pending
- 2007-07-20 CA CA2658340A patent/CA2658340C/en active Active
- 2007-07-20 ES ES07799742T patent/ES2402232T3/es active Active
- 2007-07-20 WO PCT/US2007/074036 patent/WO2008016793A2/en not_active Ceased
- 2007-08-01 TW TW96128166A patent/TWI469776B/zh not_active IP Right Cessation
- 2007-08-01 AR ARP070103398A patent/AR062177A1/es not_active Application Discontinuation
-
2009
- 2009-01-05 ZA ZA200900017A patent/ZA200900017B/xx unknown
- 2009-02-01 IL IL196825A patent/IL196825A/en not_active IP Right Cessation
- 2009-02-20 US US12/390,376 patent/US8030278B2/en not_active Expired - Lifetime
- 2009-02-27 NO NO20090915A patent/NO20090915L/no not_active Application Discontinuation
-
2011
- 2011-08-29 US US13/220,358 patent/US8440620B2/en not_active Expired - Fee Related
-
2012
- 2012-12-11 US US13/711,519 patent/US8729023B2/en not_active Expired - Lifetime
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Bailly et al. | Combined cytotoxic chemotherapy and immunotherapy of cancer: modern times | |
| Nowak et al. | Systemic therapy for advanced hepatocellular carcinoma: a review | |
| Zhang et al. | Chemotherapy reinforces anti-tumor immune response and enhances clinical efficacy of immune checkpoint inhibitors | |
| Fazio et al. | Chemotherapy in gastroenteropancreatic (GEP) neuroendocrine carcinomas (NEC): a critical view | |
| JP2009545609A5 (https=) | ||
| Albany et al. | Refractory testicular germ cell tumors are highly sensitive to the second generation DNA methylation inhibitor guadecitabine | |
| JP2019521180A5 (https=) | ||
| Ajani et al. | A multi-center phase II study of sequential paclitaxel and bryostatin-1 (NSC 339555) in patients with untreated, advanced gastric or gastroesophageal junction adenocarcinoma | |
| JP2013503174A5 (https=) | ||
| WO2009120697A4 (en) | Method and compositions for treatment of cancer | |
| JP2013504582A5 (https=) | ||
| WO2014059199A1 (en) | Hemoglobin-based oxygen carrier-containing pharmaceutical composition for cancer targeting treatment and prevention of cancer recurrence | |
| RU2009107085A (ru) | Способы, композиции и изделия, способствующие лечению рака | |
| JP2023024618A (ja) | がんの処置のためのトランス－［テトラクロロビス（１ｈ－インダゾール）ルテネート（ｉｉｉ）］の使用 | |
| JP2011503039A5 (https=) | ||
| O'Dwyer | Multifaceted approach to the treatment of bcr-abl-positive leukemias | |
| JP2019507166A5 (https=) | ||
| Kaur et al. | Naturally occurring, natural product inspired and synthetic heterocyclic anti-cancer drugs | |
| Li et al. | A multi-targeted tyrosine kinase inhibitor lenvatinib for the treatment of mice with advanced glioblastoma | |
| Sun et al. | Preclinical activity of lobaplatin as a single agent and in combination with taxanes for ovarian carcinoma cells | |
| JP2010502638A5 (https=) | ||
| Kunisaki et al. | Biweekly Docetaxel and S-1 combination chemotherapy as first-line treatment for elderly patients with advanced gastric cancer | |
| Alkafaas et al. | DEXAMETHASONE IMPROVES THE RESPONSIVENESS OF HEPATOMA CELLS FOR BOTH FREE AND SOLVENT CONTAINING PACLITAXEL IN VITRO. | |
| Park et al. | Salvage chemotherapy with irinotecan and cisplatin in patients with metastatic gastric cancer failing both 5-fluorouracil and taxanes | |
| RU2010140611A (ru) | Комбинированное применение производных холестанола |